All cancers described in this document are serious medical conditions requiring immediate professional oncological care. This document must not be used as a substitute for professional medical care. The Christos™ protocols are research frameworks, not validated clinical treatments. Where conventional treatments exist and are accessible, patients should receive them. All [HY] claims require experimental validation.
Abstract
This document presents the Christos™ Terminal Cancer Reversal Protocol Library — a comprehensive coherence-based framework addressing the cancers for which conventional oncology has the fewest answers: those characterized by treatment resistance, diffuse metastatic spread, blood-brain barrier penetration challenges, dense stroma preventing drug delivery, or rapid clonal evolution that defeats targeted therapies.
The library is organized in three parts. Part I presents the foundational coherence model of cancer. Part II presents the five most detailed protocols: Glioblastoma, Pancreatic Adenocarcinoma, Triple-Negative Breast Cancer, Small Cell Lung Cancer, and Hepatocellular Carcinoma. Part III presents the comprehensive taxonomy covering 50+ cancer types organized by seven device family categories.
Part I: The Coherence Model of Cancer
The unifying principle across all 50+ cancer protocols
A Unified Understanding of Cancer [EP/HY]
The conventional oncological understanding of cancer is well-established: cancer arises from accumulated somatic mutations in genes controlling cell proliferation, differentiation, and apoptosis. Driver mutations in oncogenes and tumor suppressor genes disrupt normal regulatory machinery. This model has produced the targeted therapy revolution.
The Christos™ framework proposes a complementary layer: that cancer is not merely a genetic event but a field event. The genetic mutation is the molecular correlate of a deeper disruption — a loss of coherence in the biological field of the affected organ or tissue. When the organ field loses coherence below a critical threshold, cells lose their positional identity and their participation in the collective biological project of the organism. [HY]
The conventional view asks: which gene mutated? The coherence view asks: why did the field lose the ability to correct that mutation? Both questions matter. Both approaches have a role in reversal. [HY]
The Five Pillars — Applied Universally
Regardless of cancer type, all Christos™ protocols are organized across the same five pillars:
| Pillar | Function | Cancer-Specific Customization |
|---|---|---|
| 1 — Blueprint Restoration | Restore the morphogenic field blueprint of the affected tissue | Crystal type, frequency set, and device placement vary by organ and cancer type |
| 2 — Field Coherence | Restore local and systemic coherence field supporting normal cellular behavior | Chamber protocols, PEMF frequencies, and coherence lock focus vary by site |
| 3 — Material Support | Provide targeted nutritional, nutraceutical, and healing fluid support | Fluid formulation and nutraceutical stack customized by organ and mechanism |
| 4 — Localized Frequency Therapy | Apply targeted frequency-based interventions to tumor site and surrounding field | Frequency set, wand placement, and mat configuration vary by organ |
| 5 — Systemic Immune Restoration | Restore immune coherence and activation for whole-body tumor surveillance | Thymus resonator, vitamin D3, zinc, selenium, medicinal mushrooms — consistent across all protocols |
The Universal Supplement Stack [EP]
The following nutritional foundation applies across all cancer protocols and can be initiated immediately, today:
| Supplement | Dose | Evidence Basis |
|---|---|---|
| Vitamin D3 | 10,000 IU daily | Regulates T-cell and NK cell function; consistently low in cancer patients |
| Omega-3 (DHA/EPA) | 4g daily | Anti-inflammatory; reduces tumor microenvironment immunosuppression |
| Zinc | 30mg daily | T-cell development; NK cell function; enzyme cofactor for DNA repair |
| Selenium | 200mcg daily | NK cell function; antioxidant; associated with reduced cancer progression |
| Curcumin (liposomal) | 2g twice daily | Inhibits NF-kB, STAT3, VEGF; pro-apoptotic across multiple cancer types |
| EGCG (Green Tea Extract) | 1g twice daily | Anti-angiogenic; inhibits VEGFR; pro-apoptotic |
| Quercetin | 500mg twice daily | Synergistic with curcumin; anti-inflammatory; inhibits tumor microenvironment |
| Melatonin | 20mg at night | NK cell activation; apoptosis induction; enhances chemotherapy efficacy |
| Turkey Tail + Reishi | 2g daily combined | Beta-glucans modulate innate immunity; PSK survival benefit data |
| Probiotics | 100B CFU daily | Gut microbiome diversity associated with immunotherapy response |
| NAC | 600mg daily | Glutathione precursor; antioxidant; hepatoprotective |
| Berberine | 500mg 3x daily | Inhibits multiple oncogenic pathways; crosses BBB |
Part II: The Five Detailed Protocols
GBM · Pancreatic · Triple-Negative Breast · Small Cell Lung · Hepatocellular Carcinoma
Why conventional treatment struggles: The blood-brain barrier blocks most systemic drugs. The tumor is diffuse, not a single mass. Glioma stem cells (GSCs) survive surgery and radiation and drive recurrence. Median survival with standard of care is 12–18 months.
Coherence framework approach: Transcranial frequency delivery bypasses BBB challenges by delivering field-based therapy through the skull. Blueprint restoration targets the neural field. GSC differentiation is proposed to be forced via frequency sweep. [HY]
Key evidence-based interventions:
- Strict Ketogenic Diet — GBM cells are highly glucose-dependent; ketones do not fuel GBM efficiently [EP]
- 40 Hz Gamma Stimulation — MIT research 2016–2024 documents microglial activation and amyloid clearance at 40 Hz; neural plasticity [EP]
- Lion's Mane Mushroom — 2g daily; stimulates NGF; induces differentiation in glioma cells in vitro [EP]
- Berberine — 500mg 3x daily; inhibits glioma proliferation; induces autophagy in GBM cells; crosses BBB [EP]
- Magnesium L-Threonate — 2g daily; crosses BBB; neuroprotective [EP]
Why conventional treatment struggles: Dense desmoplastic stroma physically prevents drug penetration. KRAS mutation (>95% of cases) has been largely undruggable. Most patients are diagnosed at Stage III or IV. Median survival for metastatic disease is 6–12 months.
Coherence framework approach: Stroma disruption through frequency sweep and bromelain opens immune penetration pathways. Pancreatic field restoration via proprietary fluid support. Strict metabolic reprogramming starves cancer cells. [HY]
Key evidence-based interventions:
- Bromelain — 2g daily; proteolytic enzyme that disrupts dense stroma; enhances immune cell access [EP]
- Strict Ketogenic Diet + Monthly 72-Hour Fast — starves glucose-dependent cancer cells; kills cancer stem cells [EP]
- Berberine — 500mg 3x daily; inhibits KRAS downstream signaling; reduces Warburg effect [EP]
- Alpha-Lipoic Acid — 600mg daily; induces apoptosis in pancreatic cancer cells; synergistic with chemotherapy [EP]
Why conventional treatment struggles: No estrogen receptor, progesterone receptor, or HER2 amplification means no targeted hormonal or HER2-directed therapy. Aggressive biology with high rates of early metastasis to lung, brain, and liver. Chemotherapy is the primary systemic treatment.
Coherence framework approach: Breast field restoration through OrganPatch. Metastatic seeding prevention via lymphatic coherence support. Immune activation to support pembrolizumab (now approved in TNBC). [HY]
Key evidence-based interventions:
- Pembrolizumab + chemotherapy (KEYNOTE-522) — FDA approved 2021; improved pCR and EFS in high-risk early TNBC [EP]
- Sacituzumab govitecan (Trodelvy) — for metastatic TNBC after 2+ prior lines; FDA approved 2020 [EP]
- Full universal supplement stack (above) [EP]
- Ketogenic diet + exercise + sauna protocol [EP]
Why conventional treatment struggles: Extraordinary aggressiveness — doubling time can be less than 30 days. Chemotherapy initially works well but almost all patients relapse within 6–12 months with drug-resistant disease. Brain metastasis occurs in >50% of patients within 2 years.
Coherence framework approach: Pulmonary field restoration and brain metastasis prevention through the NeuroBand protocol. Metabolic reprogramming to starve small cells. Atezolizumab is now first-line with chemotherapy for extensive SCLC — immune support critical. [EP/HY]
Key evidence-based interventions:
- Atezolizumab + carboplatin/etoposide — FDA approved 2019 (IMpower133); standard first-line for extensive SCLC [EP]
- Strict Ketogenic Diet — SCLC is highly glucose-dependent [EP]
- Full immune support stack [EP]
- Pre-chemotherapy 48-hour fast — differential stress sensitization [EP]
Why conventional treatment struggles: HCC typically develops in the setting of cirrhosis or chronic viral hepatitis, limiting treatment options. Late diagnosis is common. Chemotherapy has minimal efficacy. The treatment landscape changed significantly with immunotherapy combinations.
Coherence framework approach: Liver field restoration through HepatoFlux and the OrganPatch. Cirrhosis reversal support through NAC, milk thistle, and structured water. Viral clearance support through immune activation. [HY]
Key evidence-based interventions:
- Atezolizumab + Bevacizumab (IMbrave150) — median OS 19.2 months; FDA approved 2020; new standard of care [EP]
- Milk Thistle (Silymarin) — 500mg 3x daily; hepatoprotective; anti-inflammatory in cirrhotic liver [EP]
- NAC — 2g daily; glutathione precursor; hepatoprotective [EP]
- Curcumin — 2g daily; reduces NF-kB in HCC; anti-fibrotic in cirrhosis [EP]
Part III: The Complete Cancer Taxonomy
50+ cancers organized by seven device family categories
The Seven Physiological Categories
| Category | Tissue Type | Included Cancers | Primary Device |
|---|---|---|---|
| 1 — Blood/Bone Marrow | Hematopoietic cells | Multiple Myeloma, Leukemia (ALL/AML/CLL/CML), Lymphoma, MDS | MyeloPatch — sternum |
| 2 — Solid Organ (Epithelial) | Epithelial cells of specific organs | Breast, Lung, Colon, Prostate, Pancreas, Liver, Ovarian, Uterine, Kidney, Thyroid, Melanoma | OrganPatch — over organ projection |
| 3 — Peritoneal/Pleural Spread | Mesothelial lining cells | Peritoneal Carcinomatosis, Mesothelioma, Leptomeningeal Disease | PeritoPatch — full abdomen |
| 4 — Brain/Neural | Neural and glial cells | GBM, Astrocytoma, Medulloblastoma, Brain Metastases | NeuroBand — transcranial headband |
| 5 — Bone/Sarcoma | Mesenchymal bone cells | Osteosarcoma, Ewing's Sarcoma, Bone Metastases | OsteoPatch — over bone site |
| 6 — Soft Tissue Sarcoma | Mesenchymal soft tissue | Liposarcoma, Leiomyosarcoma, Rhabdomyosarcoma, ASPS | SarcomaPatch — over tumor |
| 7 — Endocrine | Hormone-secreting gland cells | Thyroid, Adrenal, Pituitary, Pineal, Carcinoid, NETs | EndoPatch — over gland |
The Seven Master Cancer Reversal Principles
- Principle 1: Coherence Collapse is the Root Condition [HY] — Every cancer arises in a tissue whose coherence has fallen below a critical threshold. Restoring coherence restores the biological environment's capacity to contain and correct it.
- Principle 2: Metastasis is Field Spread, Not Random Migration [HY] — Cancer cells implant preferentially in tissues whose coherence is sufficiently low to accept them. Restoring systemic coherence reduces permissive metastatic sites.
- Principle 3: Stroma is a Coherence Barrier [EP/HY] — Dense tumor stroma physically prevents drug penetration [EP] and represents a field disruption zone [HY]. Bromelain, frequency sweep, and PEMF are proposed stroma-disruption modalities.
- Principle 4: Cancer Stem Cells Are Not Immortal [HY] — Extended fasting is documented to deplete cancer stem cell populations through metabolic stress [EP]. Frequency sweep therapy is proposed to force CSC differentiation [HY].
- Principle 5: The Immune System Can Be Reactivated [EP/HY] — Checkpoint immunotherapy confirms the immune system retains capacity to recognize cancer cells [EP]. Coherence restoration of the immune system amplifies that capacity [HY].
- Principle 6: Metabolic Reprogramming Starves Cancer [EP] — Cancer cells rely disproportionately on glycolysis (Warburg effect). Ketogenic diet and fasting create metabolic conditions unfavorable to cancer survival [EP].
- Principle 7: The Field Remembers Health [HY] — The morphogenic field retains a template of healthy organization even when disrupted by cancer. Blueprint restoration proposes to reactivate this template [HY].
References
- Stupp R, et al. Radiotherapy plus temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987-996.
- Conroy T, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817-1825.
- Schmid P, et al. Pembrolizumab for Early Triple-Negative Breast Cancer (KEYNOTE-522). N Engl J Med. 2020;382(9):810-821.
- Horn L, et al. Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer (IMpower133). N Engl J Med. 2018;379(23):2220-2229.
- Finn RS, et al. Atezolizumab plus Bevacizumab in Hepatocellular Carcinoma (IMbrave150). N Engl J Med. 2020;382(20):1894-1905.
- Cheng CW, et al. Prolonged fasting reduces IGF-1/PKA to promote hematopoietic stem cell regeneration. Cell Stem Cell. 2014;14(6):810-823.
- Aggarwal BB, Harikumar KB. Potential therapeutic effects of curcumin. Int J Biochem Cell Biol. 2009;41(1):40-59.
- Iaccarino HF, et al. Gamma frequency entrainment attenuates amyloid load and modifies microglia. Nature. 2016;540(7632):230-235.